Storia in 4 fonti

FDA approves Roivant therapy for rare autoimmune disease

The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo2 g fa

FDA approves Roivant therapy for rare autoimmune disease

The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.

originale

Timeline cronologica

giovedì 27 agosto 2026·statnews.com
FDA approves Roivant therapy for rare autoimmune disease
The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.
giovedì 27 agosto 2026·endpoints.news
Roivant’s road to a potential blockbuster begins with Lisraya FDA approval
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across indications.

fiercepharma.com

1 g fa

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a rare skin disease. | Though not without…

Leggi questa versione → originale

biopharmadive.com2 g fa

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

Leggi questa versione → originale

endpoints.news2 g fa

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across indications.

Leggi questa versione → originale

venerdì 28 agosto 2026·

biopharmadive.com

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

venerdì 28 agosto 2026·

fiercepharma.com

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing its first approval in a…